Value of Heart Rate Lowering Therapy in Acute Myocarditis

Assiut University150 enrolled

Overview

To study the value of heart rate lowering therapy "pharmacological rest" on the short term in cases of myocarditis without LV dysfunction.

Study Type

OBSERVATIONAL

Enrollment

150

Conditions

Myocarditis

Interventions

IvabradineDRUG

heart rate lowering therapy

Eligibility

Sex: ALLMin age: 18 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adults: ≥18 years of age. * Presentation: at least one of the following: * Myopericarditis/ACS-like * MINOCA * Arrhythmias: brady or tachyarrhythmias. * Unexplained compensated acute cardiomyopathy (excluded ischemic, valvular, hypertensive, metabolic, and toxic causes of cardiomyopathy as indicated clinically). * TTE: LVEF\>40% * CMR-confirmed myo(peri)carditis (Lake Louise criteria) Exclusion Criteria: * • Rheumatic carditis. * Connective tissue diseases (-ve ANA). * Cancer chemotherapy. * Toxicity from immunotherapy. * Vaccine-related myocarditis. * Presence of coronary artery disease. * Peripartum (occurring during the last month of pregnancy or within 5 months after delivery) * ECG: atrial fibrillation/flutter. * Resuscitated sudden death. * Early/initial phase of decompensated heart failure. * Tamponade complicating pericarditis unless successfully managed.

Locations (1)

Heart Hospital

Asyut, Egypt

RECRUITING

Outcomes

Primary Outcomes

Value of Heart Rate Lowering Therapy in Acute Myocarditis

To study the value of heart rate lowering therapy "pharmacological rest" on the short term in cases of myocarditis without LV dysfunction.

Time frame: baseline

Central Contacts

sara mahmoud

CONTACT

01016862195 saramahmoud199783@gmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.